Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$15.2MCash on Hand
8.3mo Cash Runway
3.4%Short Interest
$4.5Analyst Target (2)
Follow PDSB by emailGet an email when PDSB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PDSB, unsubscribe in one click. Privacy
📣 What PDSB Says Is Next
Q4 2026 · “Promising interim PFS of 9.6 months reported for mCRPC in Q1 2026. 14 Five data readouts anticipated between Q4 2026 and Q2 2028, beginning with interim results in biochemically recurrent prostate cancer.”
Company press release, Oct 21, 2026 · SEC filing
Q4 2026 · “Near-Term Catalysts Five PDS0301 data readouts anticipated between Q4 2026 and Q2 2028 across biochemically recurrent prostate cancer, metastatic castration-resistant prostate cancer, colorectal cancer with liver metastases, and Kaposi sarcoma. 3 Pipeline of Tumor-Targeted Immunotherapies ChemoRT = chemoradiotherapy; HAIP = hepatic artery infusion pump; ICI = immune checkpoint inhibitor.”
Company press release, Oct 21, 2026 · SEC filing
Q4 2026 · “Five data readouts anticipated between Q4 2026 and Q2 2028, beginning with interim results in biochemically recurrent prostate cancer.”
Company press release, Sep 21, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 net loss of $7.6 million, or $0.11 per share, versus $9.0 million a year earlier, with cash of $15.2 million at September 30, 2026. R&D fell to $2.1 million from $4.6 million. Initial closing of a PIPE of up to $22.3 million led by Nant Capital was completed. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Financing NantWorks exercised warrants for 17,699,115 shares (or pre-funded warrants) at $0.22 per share, bringing gross proceeds of approximately $3.9 million. Shares for part of the exercise were issued as pre-funded warrants at $0.00033 due to a 19.9% beneficial ownership limit. Form 8-K · SEC filing · Press release
Oct 21, 2026 ·
PDS Biotech updated its corporate presentation deck on October 20, 2026, filed as Exhibit 99.1. The deck reports PDS0301 response rate of 71.4% at six months and PDS0101 median overall survival of 39.3 months. Form 8-K · SEC filing · Press release
Oct 20, 2026 ·
Leadership Four directors resigned effective October 18, 2026, including Otis Brawley, M.D., Stephen Glover, Kamil Ali-Jackson and Gregory Freitag, none over a disagreement. Deborah A. Ramsdell, John A. Dawson CBE and Bruce Wendel were appointed to fill three seats, bringing the Board to seven. Form 8-K · SEC filing · Press release
Oct 14, 2026 ·
Financing PDS Biotechnology filed a resale registration statement covering up to 110,001,540 shares tied to a September 2026 private placement with accredited investors. The company will not receive proceeds from resales but may receive cash from warrant exercises. Common warrants carry an exercise price of $0.22 per share. Form S-3 · SEC filing
Oct 6, 2026 ·
PDS Biotech will host a virtual key opinion leader event on October 15, 2026, at 8:00 AM ET, featuring Dr. Jonathan M. Hernandez of the NCI Center for Cancer Research to discuss clinical outcomes from the PDS0301 Phase 2 trials in liver-associated cancers, focusing on metastatic colorectal cancer. Form 8-K · SEC filing · Press release
Sep 22, 2026 ·
Clinical trial Published Phase 2 VERSATILE-002 results of PDS0101 with pembrolizumab in HPV16-positive recurrent/metastatic head and neck cancer in JAMA Oncology. ICI-naive median overall survival was 39.3 months versus 17.9 months for standard of care, and objective response rate was 36% in the CPS 1 or higher population. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2025 · Phase 2 · Results Expected · Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC Registry primary completion date, not a results date
Dec 2015 · Phase 1 · Results Expected · An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not PDSB's own candidates): Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PDSB holds $15.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $5.5M/quarter from operations,
an estimated runway of 8.3 months at that rate (BioRadar estimate, not company guidance).
Share count 105,005,429 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
📈 Recent Insider Activity (Form 4)
Trade date
Insider
Transaction
Shares
Price
Owned after
2026-10-18 filed 2026-10-21
Dawson John Andrew
Option award (A)
22,700
–
–
2026-10-18 filed 2026-10-20
Ramsdell Deborah
Option award (A)
22,700
–
–
2026-10-18 filed 2026-10-20
Wendel Bruce
Option award (A)
22,700
–
–
2026-01-12 filed 2026-03-03
BEDU-ADDO FRANK
Option award (A)
548,782
–
–
2026-01-12 filed 2026-03-03
CONN GREGORY
Option award (A)
150,000
–
–
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
Get the full PDSB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PDSB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.